NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer
Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapy Trial reinforces Agendiaโs progress in developing practice-changing evidence to improve personalized cancer care Read More
Updated NCCNยฎ Guidelines Recognize MammaPrintยฎ UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates
Includes level one evidence that MammaPrint can help prevent unnecessary chemotherapyยน and endocrine therapyยฒ Con๏ฌrms Agendiaโs unique ability to identify tumors that have a very low risk of distant metastasis which can have implications for Read More
Agendia Level 1B Evidence Shows MammaPrint is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients
Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium (SABCS) will illustrate MammaPrintโs ability to identify strongest candidates for extended endocrine therapy among HR+HER2- post-menopausal women December 08, 2022 09:00 AM Eastern Standard Time Read More
